PhaseV

ML for Clinical Trial Optimization

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in January 2023 by Raviv Pryluk, Dan Goldstaub, and Elad Berkman, PhaseV operates with 11–50 employees. The company has raised $65 million across 2 funding rounds from 6 investors. In May 2025, PhaseV secured a Series A funding round co-led by Accel and Insight Partners.

Business overview

PhaseV develops a platform designed to optimize clinical trial design and execution. The company leverages an intuitive user interface, flexible software architecture, and advanced algorithms, including reinforcement learning and causal machine learning, to support critical clinical decisions throughout a trial. PhaseV operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Clinical Workflow, serving the healthcare industry.

Strategic signal

In March 2026, PhaseV launched its AI Conductor, a centralized platform aimed at automating clinical workflows from protocol design to submission. This development signals a significant step towards streamlining the complex and often fragmented processes in clinical trials, offering investors a view into the company's commitment to enhancing efficiency and reducing operational burdens within the biopharma industry through advanced AI/ML solutions.

Company Intelligence Q&A

What was PhaseV's most recent funding round?
In May 2025, PhaseV completed a Series A funding round co-led by Accel and Insight Partners.
What is the purpose of PhaseV's AI Conductor?
PhaseV launched its AI Conductor in March 2026 as a centralized platform designed to automate clinical workflows, from initial protocol design through to submission, enhancing efficiency in clinical development.
Has PhaseV announced any recent partnerships?
In May 2025, PhaseV announced a strategic collaboration with the Crohn's & Colitis Foundation to advance research into Inflammatory Bowel Disease (IBD).
What new platform capabilities did PhaseV unveil in 2024?
In September 2024, PhaseV unveiled the latest capabilities of its AdaptV platform, which is designed to improve oncology clinical trials using machine learning.
When was PhaseV founded and by whom?
PhaseV was founded in January 2023 by Raviv Pryluk, Dan Goldstaub, and Elad Berkman.

External links